gdc

Newsworthy

FDA NewsLeukemiaNewsworthy
October 2018 Vol 4 No 5 – October 17, 2018
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
FDA NewsLiver CancerNewsworthy
October 2018 Vol 4 No 5 – October 17, 2018
Previously approved for thyroid cancer and kidney cancer, the FDA has recently approved Lenvima as the first treatment for patients with liver cancer.
FDA NewsKidney CancerNewsworthy
October 2018 Vol 4 No 5 – October 17, 2018
The use of Opdivo with Yervoy is the first immunotherapy combination therapy approved by the FDA for patients with kidney cancer.
Page 1 of 6
Results 1 - 10 of 55

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country